Skip to content

PERCEVAL PVS25 (UDI 08022057014719)Recalls & reported problems

Corcym Srl · DI for Perceval Size L · Class 3 · Implant

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
3
Deaths reported
0
Injuries reported
3
Recalls naming it
0

Summary

The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 08022057014719), received between Dec 17, 2021 and Sep 4, 2025 — classified as 3 injuries.

The most frequently reported specific device problem is “Insufficient Device Problem Information” (2 reports).

1 other recall cover devices cleared under the same FDA submission (P150011); they may or may not involve this specific model.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 1 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Insufficient Device Problem Information2
  • Degraded1

Patient problems

  • Thrombocytopenia2
  • Aortic Valve Stenosis1

Recent adverse event reports

The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.

  • InjurySep 4, 2025Degraded; Degraded

    INFORMATION OBTAINED FROM A PUBLISHED PAPER ENTITLED: " EMERGENCY TRANSCATHETER AORTIC VALVE IN SUTURELESS VALVE REPLACEMENT FOR MANAGING CARDIOGENIC SHOCK", BY ALESSANDRO COMIS, ET AL. THE ABSTRACT INDICTED THE FOLLOWING: ¿SUTURELESS AORTIC BIOPROSTHESIS (SBVS) MAY POSE SPECIFIC CHALLENGES TO VALVE-IN-VALVE (VIV) IMPLANTATION, PARTICULARLY, IN THE SETTING OF CARDIOGENIC SHOCK WHICH REMAINS CHALLENGING AND UNDERSTUDIED. PAPER REPORTS A PATIENT WITH A SBVS DISFUNCTION, PRESENTING WITH ACUTE DECOMPENSATED HF. DESPITE INTRA-AORTIC BALLOON PUMP (IABP), CLINICAL DETERIORATION PROMPTED AN EMERGENCY TRANSCATHETER VIV. COMPUTER TOMOGRAPHY IMAGING CONFIRMED PROCEDURAL FEASIBILITY. A SELF-EXPANDING EVOLUT PRO+ VALVE WAS DEPLOYMENT FOLLOWED BY POST-DILATATION FOR UNDER EXPANSION. THE PROCEDURE RESTORED VALVE FUNCTION, AND THE PATIENT WAS WEANED OFF IABP. AT 30-DAY FOLLOW-UP, PATIENT WAS IN NYHA CLASS I WITH COMPLETE RECOVERY OF LEFT VENTRICULAR SYSTOLIC FUNCTION (EF 53%). CAREFUL CT PLANNING AND DEVICE SELECTION ARE CRITICAL. DESPITE THE LACK OF DATA IN THIS SETTING, VIV MAY REPRESENT A SAFE AND EFFECTIVE OPTION FOR HIGH-RISK PATIENTS IN CARDIOGENIC SHOCK (CS)¿. BASED ON THE FURTHER INFORMATI

    Patient problems: Aortic Valve Stenosis

    MAUDE report 22961137 ↗
  • InjuryDec 17, 2021Insufficient Device Problem Information; Insufficient Device Problem Information

    ON (B)(6) 2021, A PERCEVAL VALVE PVS25 WAS IMPLANTED IN A PATIENT. THE PATIENT IS RECENTLY DIAGNOSED WITH PNEUMONIA AND STARTED ON ANTIBIOTIC. THE POST-OPT RECOVERY WAS PROLONGED (STILL IN ICU DUE TO THROMBOCYTOPENIA). THE PATIENT HAS BEEN UNDER OBSERVATION SINCE 1 DAY POSTOP UNTIL (B)(6) 2021. IT IS PRESENTLY UNKNOWN IF THE PATIENT RECOVERED OR IS STILL UNDER TREATMENT. THE PATIENT¿S PRE-OPERATIONAL ASSESSMENT HAS NO OTHER COMORBID CONDITION BESIDE THE OLD AGE. THE PATIENT WAS TESTED WITH A SUPPORT OF A HEMATOLOGIST AND THE RESULT TESTED NOTHING RELATED TO PATIENT'S PLATELET. THE PERCEVAL VALVE WAS SUSPECTED AS A POSSIBLE CONTRIBUTING FACTOR TO THROMBOCYTOPENIA.

    Patient problems: Thrombocytopenia

    MAUDE report 13030538 ↗
  • InjuryDec 17, 2021Insufficient Device Problem Information; Insufficient Device Problem Information

    ON (B)(6) 2021, A PERCEVAL VALVE PVS25 WAS IMPLANTED IN A PATIENT. THE PATIENT IS RECENTLY DIAGNOSED WITH PNEUMONIA AND STARTED ON ANTIBIOTIC. THE POST-OPT RECOVERY WAS PROLONGED (STILL IN ICU DUE TO THROMBOCYTOPENIA). THE PATIENT HAS BEEN UNDER OBSERVATION SINCE 1 DAY POSTOP UNTIL (B)(6) 2021. IT IS PRESENTLY UNKNOWN IF THE PATIENT RECOVERED OR IS STILL UNDER TREATMENT. THE PATIENT¿S PRE-OPERATIONAL ASSESSMENT HAS NO OTHER COMORBID CONDITION BESIDE THE OLD AGE. THE PATIENT WAS TESTED WITH A SUPPORT OF A HEMATOLOGIST AND THE RESULT TESTED NOTHING RELATED TO PATIENT'S PLATELET. THE PERCEVAL VALVE WAS SUSPECTED AS A POSSIBLE CONTRIBUTING FACTOR TO THROMBOCYTOPENIA.

    Patient problems: Thrombocytopenia

    MAUDE report 13030408 ↗

Recalls under the same FDA submission

These recalls involve devices cleared under P150011. One submission often covers many models, so check the product and lot details in each record.

  • Z-0716-2017 · Oct 31, 2016 · Terminated
    Perceval Sutureless Aortic Heart Valve size S, Item # ICV1208, REF PVS21; Perceval Sutureless Aortic Heart Valve size M, Item # ICV1209, REF PVS23; Perceval Sutureless Aortic Heart

Other Heart-Valve, Non-Allograft Tissue devices

All Heart-Valve, Non-Allograft Tissue devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page